Abstract | Understanding of chronic heart failure (HF) has progressed from a syndrome of disordered hemodynamics caused by alterations in the structure of the heart to one that involves intertwined molecular pathways in disarray. Accordingly, the assessment and treatment of patients with chronic HF has shifted from a focus on hemodynamics to modification of maladaptive molecular processes. Accumulating evidence shows that molecular biomarkers of disease could provide a unique window into the pathophysiology of chronic HF, potentially improving our ability to predict adverse outcomes, provide novel drug targets, and even help gauge therapeutic efficacy. The more 'traditional' biomarkers such as cardiac troponin, natriuretic peptides, and C-reactive protein have been studied in large cohorts of patients with chronic HF and have relatively established clinical applications. In this Review, we summarize the properties, clinical data, and potential applications of some emerging biomarkers that could uniquely indicate the level of biomechanical stretch, inflammation, ventricular remodeling, myocardial injury, and renal dysfunction that occurs in chronic HF. We will also discuss the potential role for these biomarkers within a multimarker-based strategy that could, in the future, lead to better care for these patients.
Introduction
Chronic heart failure (HF) is a complex clinical syndrome that represents the end stage of various cardiac diseases and is characterized by the inability of the heart to meet the metabolic demands of the body. Chronic HF is a major cause of world-wide morbidity and mortality, affecting more than 5.6 million people in the USA, and 23 million people worldwide. 1 Although chronic HF has existed at least since the days of Hippocrates in ancient Greece when physicians recorded its cardinal signs and symptoms, how we describe, evaluate, and treat this syndrome has changed substantially alongside several paradigm shifts in our understanding of the disease. 2 For example, over the past 2 decades, the once-held view of chronic HF as a syndrome of disordered hemodynamics and fluid balance caused by alterations in the structure of the heart has been succeeded by a view of the disease that involves molecular pathways in disarray. 2 Chronic HF is now seen as a systemic illness that involves interplay between myocardial factors, systemic inflammation, renal dysfunction, and neurohormonal activation. Our assessment and treatment of patients with chronic HF has, thus, progressed from a focus on improving hemodynamics to measuring and modifying the maladaptive molecular processes that contribute to progression of disease. 3 In this Review, we summarize the properties, clinical data, and potential applications of some emerging biomarkers that uniquely capture the levels of biomechanical stretch, inflammation, ventricular remodeling, myocardial injury, and renal dysfunction that occur in chronic HF. We will also discuss the potential role for these biomarkers within a multimarker-based strategy that could lead to more-effective care of patients with chronic HF. We have restricted our discussion to those novel biomarkers that have shown substantial promise as prognostic or therapeutic tools, and have been evaluated in large cohorts of patients with chronic HF.
The 'biomarker' paradigm in chronic HF
The 'traditional' clinical evaluation of patients with suspected chronic HF involves a combination of medical history, physical examination, chest radiography, electro cardiography, and standard laboratory assessments. These approaches have been shown to be somewhat unreliable, 4 and the need to classify chronic HF on a molecular level has prompted the widespread use of natriuretic peptides for the diagnosis, assessment, and treatment of chronic HF. [4] [5] [6] [7] B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are two peptides derived from the same precursor molecule that is synthesized by ventricular myocytes in response to hemodynamic stress. These natriuretic peptides are extremely useful in determining whether HF is the cause of acute dyspnea. Additionally, their measurement in patients with chronic HF provides powerful information about prognosis, which has led to their investigation as targets for HF therapy, with the concept that HF management 'guided' by natriuretic peptides would be superior to standard HF therapy alone. 8 The measurement of natriuretic peptides in combination with other established biomarkers of chronic HF that indicate myocardial necrosis (cardiac troponins; cTn) and inflammation (C-reactive protein measured with a high-sensitivity assay; hs-CRP) appear to improve risk prediction. 9, 10 Nevertheless, the complexity of biochemical networks that underlie the pathophysiology of chronic HF suggests that not even measurement of established markers accurately reflects all the features of the disease, and that the combined use of several indices might be required for comprehensive characterization of this syndrome.
Over the past 2 decades, new classes of blood-derived biomarkers have emerged that could provide improved insight into the complex processes that characterize the disease ( Figure 1 and Table 1) . 3 The discovery and clinical implementation of these biomarkers could present novel opportunities to improve understanding of chronic HF and the care of patients with this disease. Specifically, applying a multimarker approach that reflects the variety of molecular processes involved in chronic HF might allow for improved diagnosis, treatment, and manage ment (Figure 2 ).
Although the term 'biomarker' can be used to indicate the results of standard laboratory tests, physiological tests, and tissue biopsies as well as genetic variants and clinical images, for the purposes of this Review, we will focus on some of the protein-based, individual, novel biomarkers that have been evaluated over the past decade in large cohorts of patients with chronic HF. Although no formal categories of biomarkers exist, we will classify novel biomarkers according to the broad categories of patho physiological processes that they represent with the caveat that, owing to the interactive nature of the biology of chronic HF, some overlap may exist (Figure 1 ). Several bio markers have been characterized for each of these processes; these vary greatly in ease of measurement, cost, turnaround time, and evaluation in the clinical setting.
Myocardial stress
Mid-regional pro-adrenomedullin Adrenomedullin is a 52-amino-acid peptide with potent vasodilatory and natriuretic effects, first isolated in 1993 from human pheochromocytomas. 11 Various cells within the cardiovascular system, including vascular endo thelial cells, smooth muscle cells, cardiac fibroblasts, and myocytes, have been shown to secrete adrenomedullin, and Key points ■ Chronic heart failure is a major health problem that results from maladaptive signaling within intertwined molecular pathways ■ Several novel biomarkers have been identified that allow measurement of the multitude of molecular processes involved in the pathophysiology of chronic heart failure ■ The clinical use of biomarkers could result in improved diagnosis, risk assessment, and treatment of patients with chronic heart failure ■ Considerable interest exists in the use of a multimarker strategy for parallel evaluation of traditional and novel biomarkers in patients with chronic heart failure ■ The goal of a multimarker strategy would be to classify chronic heart failure on a molecular basis and tailor therapies accordingly ■ New therapies for chronic heart failure could emerge from the measurement of novel biomarkers in patients with this condition mRNA levels of this hormone are upregulated in response to hemodynamic stress. 11 The cardiovascular effects of adrenomedullin occur via increased concentrations of its second messenger cAMP in vascular smooth muscle and by simulation of endothelial cells to release nitric oxide. 12 Upregulation of adrenomedullin in cardiac disease appears to represent a cardioprotective mechanism, especially given its favorable effects on cardiac hemodynamics. 13, 14 Plasma levels of adrenomedullin are elevated in chronic HF as well as in various other diseases, including athero sclerosis, arterial hypertension, pulmonary hypertension, glomerulonephritis, chronic renal failure, and sepsis.
14 In patients with chronic HF, adrenomedullin level is positively correlated with NYHA classification and left ventricular end diastolic pressure (LVEDP). [15] [16] [17] Initial clinical studies showed that adrenomedullin level has independent prognostic utility in patients with systolic HF and identified patients who would benefit from β-blocker therapy. 17, 18 However, clinical application of adrenomedullin measurement has been impeded by unreliability of plasma measurements; the peptide has a plasma half-life of 22 min and is bound to a specific protein in the plasma. 19 Fortunately, assays are now available that can detect the stable prohormone, fragment mid-regional pro-adrenomedullin (MR-proADM), levels of which mirror those of the mature hormone. 20 Several studies in patients with varying degrees of chronic HF have shown that an elevated level of MR-proADM is strongly associated with adverse outcomes, independent of established risk factors such as increased levels of BNP and creatinine, reduced left ventricular ejection fraction (LVEF), and NYHA class. 14, 17, 21 However, data from preliminary studies are conflicting as to whether levels of MR-proADM or adrenomedullin change meaningfully in response to medical therapy. 22, 23 Although the data on the role of MR-proADM in chronic HF are promising, more information is required to establish the utility of this hormone in the clinical setting, and the resultant interventions that could be informed though its measurement.
Neuregulin 1
Neuregulin 1 (NRG-1) belongs to a family of growth factors that act through receptor tyrosine kinases in the epidermal growth factor receptor (EGFR/ErbB) family and is involved in a wide variety of cellular processes. NRG-1 is expressed in the heart and has an indispensible role in cardiac development and function. 24 Knockout mice deficient in the NRG-1/ErbB signaling cascade (NRG-1, together with its receptors ErbB2 and ErbB4) show a range of phenotypes from failure in cardiac develop ment to a dilated cardiomyopathy, implying that this pathway has a role in the pathogenesis of chronic HF. 25, 26 NRG-1/ErbB signaling has also been shown to have a key role in the pathogenesis of several human cancers and neurological disorders. 27, 28 Interest in applying the findings of animal studies to humans was prompted by the observation that women with breast cancer who were treated with the ErbB2-targeted antibody trastuzumab had an increased risk of developing cardiac dysfunction and chronic HF. 29 Ensuing observations from animal studies have confirmed the critical role of NRG-1/ErbB signaling in the response of the heart to injury, as well as maintenance of normal myo cardial structure and function. 30, 31 The specific mechanisms by which chronic HF modifies the NRG-1/ErbB signaling cascade are unclear. Peripheral infusion of NRG-1β into murine models of disease result in improved cardiac function; 32 therefore, elevations in NRG-1β are likely to have a compensatory role, particularly because ErbB receptors are downregulated in failing cardiomyocytes. 33 Evidence suggests that NRG-1 promotes cardiomyocyte growth and survival, indicating that it may be a promising drug target for the restoration of cardiac function after injury. 32, 34 The level of NRG-1 (specifically the NRG-1β isoform) can be measured in human serum using an ELISA. In a study of 899 outpatients with chronic HF, circulating levels of NRG-1β were independently associated with disease severity and risk of death or cardiac transplantation. 26 Further studies are needed to clarify whether NRG-1β could be used in risk stratification of patients with chronic HF.
Recombinant neuregulin shows promise as a novel therapy for patients with chronic HF. One recombinant NRG-1β (rhNRG-1) fragment is being tested in clinical trials in Australia and China, and another has begun early-phase human trials in the USA. 31 A phase II trial involving 44 patients with NYHA class II-III chronic HF were treated with rhNRG-1 and, after 90 days, showed a trend towards improvement in cardiac structure and function, as assessed by MRI. 35 rhNRG-1 also produces favorable acute and chronic hemodynamic effects in patients with stable chronic HF who are already receiving optimal medical therapy. 36 Whether rhNRG-1 will emerge as being safe, tolerable, and effective in patients with chronic HF remains to be seen. Therefore, NRG-1 represents a promising biomarker of cardiac failure that could also provide a therapeutic avenue for patients with elevated levels of this growth factor.
ST2
ST2 (also known as interleukin-1 receptor-like 1) is a member of the IL-1 receptor family. The role of ST2 in cardiac disease was first suggested by the identification of Il1rl1 (previously St2) as a mechanically induced gene in cultured rat cardiomyocytes; 37 ST2 was subsequently found to be elevated in patients with chronic HF. 38, 39 The expressed ST2 protein exists in both a transmembrane form (ST2L) found in cardiomyocytes, fibroblasts, and vascular endothelial cells, as well as a truncated soluble receptor (sST2) that can be detected in human serum. 40 Research in animal models has shown that the ligand for ST2 is IL-33, which is also released by cardiac fibroblasts during myocardial stretch. 41 The current hypothesis is that intact IL-33/ST2 signaling is a mechanically activated cardioprotective paracrine signaling system that shields the myocardium against the adverse effects of overload. 41, 42 Therefore, increased levels of sST2 might augment adverse remodeling by serving as a decoy receptor for IL-33, sequestering and inhibiting it, thereby compromising adequate IL-33/ST2 signaling. 41 Clinically, measurement of plasma sST2 level has important prognostic value across a spectrum of cardiac diseases, ranging from acute coronary syndromes to acute Abbreviations: ADM, adrenomedullin; ATII, angiotensin II; BNP, brain natriuretic peptide; CHD, coronary heart disease; CRS, cardio-renal syndrome; CT-proET-1, C-terminal pro-endothelin 1; GDF, growth-differentiation factor; GFR, glomerular filtration rate HF, heart failure; hs-cTn, cardiac troponins measured by a highly sensitive assay; MR-proADM, mid-regional pro-adrenomedullin; NGAL, neutrophil gelatinase-associated lipocalin; TGF, transforming growth factor.
and chronic HF. Increases in sST2 can, however, be variable and its use as a diagnostic tool is less suitable than the natriuretic peptides. 8, 43 Elevated levels of sST2 are strongly associated with measures of chronic HF severity, increased risk of death or transplantation, and sudden cardiac death in patients with chronic HF. [43] [44] [45] [46] In a study published in 2011, sST2 was equivalent to NT-proBNP in classifying risk among 1,141 ambulatory patients with chronic HF, and its addition to established predictive models improved risk stratification. 44 This finding has been confirmed in other large cohorts of patients with chronic HF. 47 Preliminary studies indicate that serial measurement of sST2 has independent prognostic value and could have a role in biomarker-directed therapy of patients with chronic HF. 7, [48] [49] [50] A high-sensitivity assay for sST2 (Presage®, Critical Care Diagnostics, Inc., New York, NY, USA) will enable detection across lower serum concentrations than is currently possible, and future studies could extend the use of sST2 measurement among patients with less-severe chronic HF. 51 Measurement of sST2 could be used for prediction of both short-term and long-term outcomes among patients with chronic HF. A study of patients admitted to hospital with an acute myocardial infarction showed that measurement of sST2 augmented the prediction of adverse left ventricular remodeling. 52 On the basis of these results, the investigators hypothesized that eplerenone might attenuate cardiac remodeling to a greater extent in patients with higher compared with lower baseline sST2 levels. 52 Ongoing research focused on serial measurements of sST2 will answer the question as to whether this biomarker can be used to guide out patient treatment of chronic HF and to determine treatment efficacy. Future clarification of the mechanisms involved in IL-33/ST2 signaling could enable targeted therapies to be developed that mimic or restore the cardio protective effects of this pathway.
Myocardial injury
High-sensitivity measurement of cTn Death of cardiomyocytes is a common outcome in a variety of pathological conditions, such as hypertension and ischemic heart disease that cause progression of chronic HF. Highly sensitive assays are now able to detect elevated levels of cTn in stable patients with chronic HF, implying that myocardial damage might be ongoing in the absence of overt clinical signs. cTn release in these patients is consistently found to be independent of obstructive epicardial coronary disease, suggesting that mechanisms other than myocardial ischemia are involved. Although not clearly understood, cTn elevation in these patients is likely to be the result of a combination of nonischemic myocardial injury, alterations in calcium handing, loss of cell membrane integrity, and excessive wall tension. 53 The use of cTn levels to risk stratify patients with both acute and chronic HF has been studied extensively. 53 In general, increasing cTn levels directly correlate with more-advanced disease, as well as the extent of decompensation. 53 Increased cTn levels are consistently associated with worse outcomes in patients with chronic HF, with several studies showing that this relationship is indepen dent of natriuretic peptide levels and other tradi tional predictors of risk. 53 However, the prevalence of 'positive' values varies greatly (6-82%) 53 according to the characteristics of the patient population being studied, the type of assay, and the cut-off level used.
Commercially available assays for cTn are compromised at the 99 th percentile reference limit. Since cTn elevations in HF generally are quite low, this characteristic Figure 2 | Possible future strategies for biomarker-guided therapies in chronic HF. The clinical presentation and characteristics of patients with chronic HF result from a combination of molecular mechanisms, some of which are now measureable using biomarkers. In the future, therefore, a multimarker approach could be used to guide the use of the therapeutic armamentarium. Traditional biomarkers appear in italics. Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; GDF, growth-differentiation factor; HF; heart failure; hs, high sensitivity; MR-proADM, mid-regional proadrenomedullin; NGAL, neutrophil gelatinase-associated lipocalin.
curbs the clinical information that can be derived from these measurements. New, increasingly sensitive assays for cTn are being developed that are an order of magnitude more sensitive, and their gradual introduction into the clinical setting is beginning to modify our understanding of cTn in chronic HF as a continuous, rather than a dichotomous, variable. 54 In a large population of patients (n = 9,698) without known coronary heart disease, cTn measured by a highly sensitive assay (hs-cTn) was associ ated with hospitalization and mortality related to HF. 55 Latini and colleagues found that the vast majority of patients with chronic HF had measureable levels of hs-cTn that increased in proportion to disease severity, and that elevated levels retained significant predictive value, even at concentrations lower than the detection limit of the traditional assay (0.01 ng/ml). 56 The highly sensitive assay was superior to the conventional cTn assay for prognosis and was additive to measurement of BNP level for this indication. 56 Other studies in patients with chronic HF support the prognostic value of hs-cTn, even in the presence of other biomarkers such as natriuretic peptides, copeptin, and sST2. [57] [58] [59] Clear evidence exists that even extremely low levels of cTn have important prognostic implications in patients with chronic HF. Whether this association persists after accounting for other biomarkers of risk, and how therapies could be modified in response to cTn elevations in patients with chronic HF is the subject of ongoing research. The use of hs-cTn to monitor medicationrelated cardio toxicity (for example, chemotherapeutic agents) has also been proposed, and the use of this biomarker as a surrogate for safety in drug trials in the near future is possible. 60 
Matrix and cellular remodeling
Galectin-3 Galectin-3 is a member of a family of soluble β-galactoside-binding lectins that play a regulatory role in inflammation, immunity, and cancer. This molecule is ubiquitously expressed in many tissues, both in the cytoplasm and in a secreted form, and interacts with a variety of intracellular and extracellular proteins to regulate several biological processes. 61 Galectin-3 was initially known for its role as a mediator of tumor growth, progression, and metastasis. New data indicate that galectin-3 represents a potential link between inflammation and fibrosis; the level of this protein is elevated in several human fibrotic conditions, including liver cirrhosis, idiopathic lung fibrosis, pancreatitis, and renal failure. 61 In chronic HF, galectin-3 augments fibrosis and modulates immune response, both of which are pivotal processes in maladaptive cardiac remodeling. [62] [63] [64] [65] Animal models have demonstrated that myocardial galectin-3 expression is low in normal hearts, but significantly upregulated in failing hearts. 62, 66 Myocardial biopsies in these animals obtained before the development of overt HF showed that increased levels of galectin-3 were associated with severe cardiac fibrosis, and that infusion of recombinant galectin-3 into the pericardial space prompted fibrosis. 62 This adverse ventricular remodeling was reversed by co-infusion with N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a tetrapeptide that blocks enhanced macrophage cell infiltration triggered by galectin-3. 67 Studies of patients with chronic HF have shown that an increased level of galectin-3 is associated with increased turnover of the extracellular matrix, parameters of diastolic dysfunction, and level of renal dysfunction. [68] [69] [70] Galectin-3 provides important prognostic information in patients with chronic HF, 60, [69] [70] [71] [72] [73] although its diagnostic role is limited relative to that of the natriuretic peptides. 74 The largest analysis to date of the association between galectin-3 level and outcomes was conducted in 895 ambulatory patients with chronic HF enrolled in the HF-ACTION trial. 74 The data revealed that, although an elevated level of galectin-3 was associated with measures of HF severity, this association did not persist after inclusion of other predictors of HF, particularly NT-proBNP.
In November of 2010, measurement of galectin-3 was approved by the FDA for use as an aid in the assessment of prognosis in patients with chronic HF. However, whether measurement of galectin-3 provides any additional prognostic information when natriuretic peptide levels are known is not clear and data on therapeutic interactions are lacking.
Growth-differentiation factor 15
Growth-differentiation factor 15 (GDF-15) is a member of the transforming growth factor-β cytokine superfamily that was first cloned as macrophage inhibitory cytokine 1, with a postulated role as an autocrine regulatory molecule. 75 GDF-15 is ubiquitously expressed at low levels in most tissues, and levels increase exponentially in response to inflammation and tissue injury. 76 Expression in cultured myocytes is triggered by ischemia, stretch, pro inflammatory cytokines, and neurohormone activation-all components of chronic HF. 77, 78 GDF-15 is hypothesized to have a role in cardiac remodeling via protection of the myocytes against apoptosis and induction of hyper trophy. 79 In 2006, Kempf et al. showed that GDF-15 also acts as an anti-inflammatory cytokine that limits leukocyte recruitment into infarcted myocardium, thereby limiting tissue damage and promoting survival. 80 Stress-induced elevations in GDF-15 are not myocyte specific; increased levels of GDF-15 are found in other cells of the cardiovascular system, such as smooth muscle cells, endothelial cells, adipocytes, and atherosclerotic plaques.
76,81 GDF-15 is also associated with activation of the protein 53 pathway in human cancers, and elevated levels of this molecule are thought to enhance tumorogenic activity. 82 Several studies have shown that elevated levels of GDF-15 are strongly associated with adverse outcomes in patients with an acute coronary syndrome and those with stable coronary heart disease, providing prog nostic information independent of more-established risk markers such as hs-CRP and cTn. [83] [84] [85] [86] The role of GDF-15 in patients with HF has been less-extensively examined. In an initial study of 455 patients with stable chronic HF, GDF-15 levels were highly predictive of mortality beyond established clinical and biochemical measurements, such as NYHA class, LVEF, and NT-proBNP level. 87 A later study showed that GDF-15 levels were strongly predictive of adverse outcomes, independent of NT-proBNP level, in 158 patients with advanced chronic HF under going resynchronization therapy. 88 A comprehensive analysis of patients enrolled in the Val-HEFT trial showed that elevated GDF-15 levels were associated with increased neurohormonal activation, inflammation, myocyte death, renal dysfunction, echocardiographic para meters of advanced chronic HF, and adverse outcomes independent of established clinical and biochemical risk markers. 76 However, although changes in GDF-15 level were related to the progression and prognosis of chronic HF, no interaction with valsartan treatment occurred. 76 These data suggest that elevated levels and changes in serial measurements of GDF-15 in plasma are independently associated with many of the clinical and biochemical characteristics of chronic HF, as well as with overall prognosis. GDF-15 may provide a window into several pathological processes in chronic HF, including neurohormonal activation, inflammation, myocyte death, adverse ventricular remodeling, and renal dysfunction. Nevertheless, more data are required to clarify the potential clinical use of GDF-15 in chronic HF, whether for prognostication, monitoring and guiding therapies, or for the development of new treatment targets. 80 
Neurohormones

Endothelin 1
Endothelin 1 (ET-1) is potent vasoconstrictor and profibrotic hormone that is primarily secreted by endothelial cells, but also by other cells involved in cardiovascular homeostasis such as cardiomyocytes, smooth muscle cells, and macrophages. ET-1 acts in a local autocrine and paracrine fashion to promote vasoconstriction and adverse vascular remodeling via its effects on the reninangiotensin-aldosterone system, vasopressin, and atrial natriuretic peptide, and stimulation of the sympathetic nervous system. 89 Increased levels of ET-1 have been noted in patients with chronic HF, but the prognostic implications of these findings are unclear, particularly in patients with advanced disease. 90 Several studies of patients with chronic HF have demonstrated independent associations between elevated levels of ET-1 and adverse outcomes, even after correction for natriuretic peptide levels. [91] [92] [93] However, other studies have failed to validate these findings. 94, 95 These inconsistencies have been suggested to relate to the short half-life, in vitro instability, low concentration range, and protein binding of ET-1. 96 The precursor fragment of ET-1, plasma C-terminal pro-endothelin 1 (CT-proET-1), is inactive in the circulation and, therefore, more stable than ET-1. 97 Reliable immunoassays are commercially available and have been tested in the clinical setting. Masson et al. showed that plasma CT-proET-1 levels were predictive of adverse outcomes among 1,237 patients with chronic HF enrolled in the GISSI-HF trial, and provided incremental prognostic value independent of BNP level. 89 This finding was confirmed in a more-recent study by Jankowska and colleagues of 491 patients with chronic HF. 96 Whether measurement of CT-proET-1 will help identify patients who might benefit from HF therapies requires further study, as does the clinical implications of treatment-induced changes in levels of ET-1 or its precursor in patients with chronic HF. 89 Further studies are also needed to ascertain whether measurement of ET-1 or CT-proET-1 might identify a subgroup of patients who could benefit from clinically available agents, such as tezosentan and bosentan, that antagonize the biological effects of this hormone. 98 Vasopressin and copeptin The peptide arginine vasopressin (AVP; also known as vasopressin-neurophysin 2-copeptin and antidiuretic hormone) is secreted from the hypothalamus in response to changes in plasma osmolarity and reduced cardiac output, as part of a defense mechanism to preserve circulatory homeostasis. The AVP level becomes elevated in response to acute illness. In patients with chronic HF, AVP secretion is chronically activated and its absolute level in plasma is related to the severity of cardiac impairment. 99 AVP is thought to have a causative role in the progression of chronic HF via its effects on free water reabsorption, cardiac contractility, and vascular tone. 100 Elevated levels of AVP have been shown to promote increased expression of aquaporin 2 channels in the renal collecting ducts, which is likely to contribute to the development of edema and hyponatremia. 101 Binding of AVP to the vasopressin 1a (V 1a ) receptors on the peripheral arterial system results in increased afterload and promotes adverse cardiac remodeling. [102] [103] Nonetheless, the direct role of AVP in the pathophysiology of chronic HF remains to be established.
The large-scale EVEREST trial showed that the oral vasopressin 2 (V 2 ) receptor antagonist tolvaptan improved signs and symptoms of chronic HF, but did not improve morbidity or mortality in hospitalized patients. 106, 107 Similarly, conivaptan, a nonselective vasopressin receptor antagonist had a favorable impact on hemodynamic parameters in patients with HF, but did not improve outcomes. 108 The plasma level of AVP is unstable, making it unsuitable as a reliable biomarker in patients with chronic HF. By contrast, the C-peptide portion of provaso pressin (copeptin), synthesized and secreted in equimolar amounts, is very stable in vitro and can be reliably measured. 109 Copeptin has emerged as a potential biomarker of a wide variety of acute conditions, and as an indicator of adequate hypothalamo-pituitary-adrenal axis activation. 110 Copeptin level has been shown to be elevated across the spectrum of chronic HF severity. Patients who have elevated copeptin levels after a myocardial infarction have increased rates of hospitalization for HF and death, independent of other risk factors. 111, 112 In patients with chronic HF, copeptin levels are highly predictive of mortality, comparable with and independent of BNP level, across the spectrum of NYHA functional class. 59,89.104,113 Alehagen and colleagues found that copeptin levels provided important prognostic information for mortality risk among patients with chronic HF over a 13-year follow-up period, and that copeptin provided additive information to NT-proBNP. 114 Whether important information can be gained from serial measurements of copeptin, either for prognostication or to check for adequacy of therapy, is still a matter of debate. 22 Copeptin levels may plausibly serve as a molecular pheno type for patients who would benefit from therapy with vasopressin antagonists, which are clinically available.
Cardio-renal syndrome
Cystatin C Cystatin C (CysC) is a cysteine protease inhibitor that is a product of a 'housekeeping' gene (CST3) with continuous expression, and is produced at a constant rate by all nucleated cells of the body. Several properties of CysC make it superior to creatinine as a measure of glomerular filtration rate (GFR) and, therefore, considerable interest exists in the potential use of CysC as a marker of both acute kidney injury and chronic renal failure. Unlike creatinine, CysC levels are unaffected by age, sex, illness, or muscle mass; they are also associated with less biological variation than creatinine levels, and are more sensitive to mild decrements in GFR. 115 The observation that renal function is a strong negative prognostic factor in patients with cardiac disease has prompted the assessment of CysC in relation to cardio vascular outcomes. Elevated levels of CysC were associated with an increased risk of all-cause mortality, cardiovascular events, and incident HF, in patients with known coronary heart disease (but no diagnosis of chronic HF), who were enrolled in the Heart and Soul Study. 116 The association between CysC levels and outcomes among patients with chronic HF has been studied on numerous occasions. [117] [118] [119] [120] [121] CysC levels increase with severity of chronic HF, as measured by NYHA class. 117, 118 Several studies have shown that CysC levels are independent predictors of adverse outcomes in patients with chronic HF, even after adjustment for creatinine level. [117] [118] [119] [120] [121] Further studies are needed to clarify the role of CysC as a measurement of renal dysfunction, an independent predictor of adverse outcomes in patients with chronic HF, and to gauge the impact of treatment on serial measurements of CysC.
Neutrophil gelatinase-associated lipocalin Neutrophil gelatinase-associated lipocalin (NGAL) is a small glycoprotein released by several types of cell, including epithelial cells, renal tubular cells, and hepato cytes, during inflammation or after injury. The role of NGAL was originally thought to be restricted to the innate immune system, but growing evidence indicates that it is also involved in other processes such as cell survival, inflammation, and matrix degradation. NGAL has been isolated as a potential marker of renal dysfunction using genomic microarray technology; transcription of the protein occurs in renal tubule cells of the thick ascending limb of Henle and the collecting duct within hours of renal injury. 122, 123 Levels of NGAL in the urine and serum peak within 24 h of the inciting event. 124 Increased serum levels of NGAL have been noted in animal models and in humans with vascular disease and chronic HF, suggesting an additional role in the pathogenesis of these diseases. 125, 126 The presence of NGAL in the setting of both renal and cardiac dysfunction could be related to an overlap in the pathological processes involved in these conditions. Measurement of NGAL levels in the urine or serum could have at least two potential uses in the clinical arena-the detection of kidney injury far before it is evident from a rise in plasma creatinine level, and as a novel risk predictor of adverse outcomes in chronic HF. 127 An analysis of 2,130 participants with chronic HF in the GISSI-HF trial showed that elevated levels of NGAL were independently associated with increased mortality, even when estimated GFR was normal. 128 Additionally, NGAL could be a potential marker for diagnosis and prognosis in patients with the cardio-renal syndrome, a clinical entity characterized by a compromise in renal function in the setting of chronic HF. 129 Preliminary data indicate that, unlike other novel markers of tubular dysfunction such as kidney injury molecular 1 (KIM-1; also known as hepatitis A virus cellular receptor 1) and N-acetyl-beta-D-glucosaminidase (NAG), NGAL levels do not change meaningfully with modulation of diuretic therapy. 130 In an animal model of acute ischemic renal injury, administration of NGAL attenuated tubular injury. 131 Further investigations are needed to clarify the role of NGAL in monitoring therapy for chronic HF, as well as to uncover any therapeutic potential of this molecule.
Box 1 | Recommendations for reporting novel risk markers 134 Report the basic study design and outcomes in accordance with accepted standards for observational studies Report levels of standard risk factors and the results of the risk model using these established factors Evaluate the novel marker in the population and report: ■ Relative risk, odds ratio, or hazard ratio conveyed by the novel marker alone, with the associated confidence limits and P value ■ Relative risk, odds ratio, or hazard ratio for novel marker after statistical adjustment for established risk factors, with the associated confidence limits and P value ■ P value for addition of novel marker to a model that contains the standard risk markers
Report the discrimination of the new marker: ■ C-index and its confidence limits for model with established risk factors ■ C-index and its confidence limits for model including novel marker and established risk markers ■ Integrated discrimination index, discrimination slope, or binary R2 for the model with and without the novel risk marker ■ Graphic or tabular display of predicted risk in cases and noncases separately, before and after inclusion of the new marker
Report the accuracy of the new marker: ■ Display observed versus expected event rates across the range of predicted risk for models without and with the novel risk marker ■ Using generally recognized risk thresholds, report the number of subjects reclassified and the event rates in the reclassified groups 
Clinical uses for novel biomarkers
The interaction between biomechanical strain, remodeling, inflammation, cardiomyocyte injury, and renal dysfunction in the pathogenesis of chronic HF could allow for a variety of biomarkers to provide a molecular 'fingerprint' of the disease that is complementary to clinical data ( Figure 1 ). Therefore, a multimarker approach has been envisioned for diagnosis, risk stratification, prognostication, and selection or titration of therapies in patients with chronic HF, and even to provide surrogate end points in clinical trials (Figure 2) . 3, 132 Despite enthusiasm for this approach, the ultimate goal of a multimarker strategy must be to generate actionable knowledge that improves patient management and outcomes, rather than merely creating greater complexity. 133 For this reason, criteria have been proposed for evaluation of novel markers of cardiovascular risk (Boxes 1 and 2) . 134 Several steps are involved in this process, the first of which is reporting of statistically sound associations between a group of biomarkers and the outcomes of interest. 135 Ideal performance characteristics vary depending on intended clinical use. 133 For screening of low-risk patients, highly specific testing is preferred whereas a high-sensitivity test is required for high-risk patients in whom false-negative results might lead to delay in treatment. For diagnosis, discrimination is critically important whereas in risk prediction, quantification of absolute risk is key. In diagnostic testing and screening, a Bayesian analysis that focuses on evaluating sensitivity and specificity are most appropriate, and tests of discrimination (c statistic) provide optimal cut-off points for clinical decision making. When panels of biomarkers are being used for prognostication, several traditional and newer statistical methods have been proposed to understand the incremental clinical benefit of additional variables that include discrimination, calibration, reclassification, and measures of fit. 136 Complex statistical modeling can be used to bypass potential drawbacks that may exist when multiple biomarkers are being considered in cohort, but translation into clinical use remains difficult and standardization of cut-off points between studies is lacking. 137 With the proliferation of novel biomarkers and the need to strike a balance between inclusion of information and minimizing complexity of analysis, utilization of alternative statistical tools might be required. One potential option is the use of artificial neural networks to analyze intricate changes in multiple biomarkers at the same time. The advantage of this approach is that a model does not have to be prespecified, and neural networks can be trained to recognize relevant patterns in data without prior knowledge of relationships. 133, 138, 139 Although important, statistical factors are merely an initial step in the evaluation of biomarkers for use in patients with chronic HF. Ideally, biomarkers deemed clinically useful should be measured simultaneously with precision from an easily obtainable biological sample, an incremental and substantial contribution to existing clinical information must be proven, results integrated with patient-related factors and reported in a simplified way (for example, a risk score) that can be applied directly to clinical decision making. This information must also be shown to improve clinical outcomes via modification of recommended therapies in a cost-effective manner. 133 The use of biomarker panels has fulfilled these criteria and transformed diagnosis and risk stratification in acute coronary syndromes, but their use in chronic HF is less-well developed. Currently, only the natriuretic peptides are widely used for diagnosis and risk assessment in chronic HF, but their use is limited to specific pathophysiological insults and interpretation of results can be confounded by comorbid conditions. Established markers that reflect additional pathological processes such as cTn and hs-CRP provide additional prognostic information, but their clinical use is limited. 3 Several studies have shown that additional important information can be obtained by measurement of novel biomarkers such as ST2, galectin-3, and copeptin. However, thus far, only pairs or triplets of biomarkers have been evaluated in a piecemeal approach and no extensive sets of biomarkers have been tested in appropriately sized and well-phenotyped cohorts of patients with chronic HF. In the future, adjustments in risk prediction models, such as the Seattle Heart Failure Model, to include plasma biomarker concentrations may improve risk assessment of patients with chronic HF. 140 Biomarkers may potentially provide a reliable and objective measure to guide therapy for chronic HF. This strategy has been almost entirely applied to BNP, with some studies suggesting improved outcomes and others showing no benefit. 141 The results of several ongoing studies will clarify the role of BNP-guided therapy in the management of chronic HF. 7, [142] [143] [144] Preliminary studies have shown that serial measurement of novel biomarkers in patients with chronic HF improves prediction of clinical outcomes, 76, 145, 146 but the effect of treatment modifications made on the basis of these measurements remains unknown. In theory, serial measurement of biomarkers Box 2 | Phases of evaluation of a novel risk marker 134 Proof of concept ■ Do novel marker levels differ between subjects with and without the outcome?
Prospective validation ■ Does the novel marker predict development of further outcomes in a prospective cohort or nested case-cohort/case-cohort study? in various 'classes' could help to provide a tailored rather than 'one size fits all' approach to treatment for chronic HF (Figure 2 ). Biomarkers are also increasingly being incorporated in clinical trials of patients with chronic HF, and many are attractive surrogates for 'global' end points such as efficacy of treatment and drug safety, particularly in early-phase studies. 60 However, the most-valid findings are likely to result from alignment of pathophysiology with the end point for which it substitutes. For example, biomarkers of hemodynamic stretch, such as the natriuretic peptides, could serve as useful surrogates for clinical end points related to hemodynamic stress, such as shortness of breath, but not for sudden cardiac death. As the characteristics of novel biomarkers are better understood, a multimarker approach that serves as a surrogate for several diverse clinical end points could be developed. At this time, the role of traditional and novel biomarkers in clinical trials remains unproven and further studies are required to elucidate their characteristics and validity as related to established HF end points.
The reasonable next step is to critically and comprehensively evaluate the added benefit of multiple biomarkers for diagnosis, management, and evaluation of new treatments in a large, well-phenotyped cohort of patients with chronic HF. Randomized, controlled trials are required to evaluate whether modifying treatment on the basis of biomarker data leads to improved patient outcomes. Once these data are available, collaboration between the research community, clinicians, and policy makers will be required to create panels of biomarkers for specific clinical indications in chronic HF. 147 
Conclusions
Chronic HF is a worldwide epidemic that results not only from mechanical dysfunction of the heart, but also from imbalances in several interconnected molecular pathways. Over the past 2 decades, a surge in the discovery of novel biomarkers has occurred that may give clinicians a unique glimpse into the molecular mechanisms of chronic HF. However, many questions remain unanswered and the time is right to apply a comprehensive panel of traditional and novel biomarkers that represent varied pathophysiological processes to well-phenotyped cohorts of patients with chronic HF, in a 'systems biology' approach to this disease. Baseline and serial measurement of biomarkers in such a population of patients could clarify their role in assessing treatment efficacy and guiding therapies. Novel biomarkers could also provide new opportunities for drug targets, the development of new therapies, and serve as surrogate end points in clinical trials. Further studies that will require collaboration between the research community and clinicians would allow us to understand the particular combination of biomarkers that provides the best utility for widespread use in the evaluation, risk stratification, monitoring of treatment and, ultimately, improvement in the care of patients with chronic HF. However, novel markers will only see clinical adaptation if their addition to the current chronic HF armamentarium improves clinical outcomes at a reasonable cost; the possibility still exists that future and ongoing studies will show that novel biomarkers do not add much to current clinical practice.
